MB
FOLD

MPM BioImpact’s Amicus Therapeutics FOLD Stock Holding History

MPM BioImpact’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-718,970
Closed -$8.47M – 45
2024
Q1 		$8.47M Buy
718,970
+3,087
+0.4% +$39.5K 1.36% 29
2023
Q4 		$10.2M Sell
715,883
-256
-0% -$2.91K 2.38% 14
2023
Q3 		$8.71M Buy
716,139
+200,000
+39% +$2.58M 2.32% 17
2023
Q2 		$6.48M Buy
516,139
+127,847
+33% +$1.52M 1.31% 24
2023
Q1 		$4.31M Sell
388,292
-12,118
-3% -$149K 1.12% 24
2022
Q4 		$4.89M Buy
400,410
+7,464
+2% +$84K 1.27% 20
2022
Q3 		$4.1M Sell
392,946
-102,657
-21% -$1.14M 0.97% 23
2022
Q2 		$5.32M Hold
495,603
– – 1.48% 21
2022
Q1 		$4.69M Sell
495,603
-17,730
-3% -$166K 1.26% 22
2021
Q4 		$5.93M Sell
513,333
-33,225
-6% -$370K 1.08% 24
2021
Q3 		$5.22M Buy
+546,558
New +$5.59M 0.81% 26

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

MPM BioImpact's FOLD Position: Q2 2024 in Review

MPM BioImpact sold out of Amicus Therapeutics (FOLD) in Q2 2024, closing a stake of 718,970 shares — an estimated $8.47M sold.

MPM BioImpact first reported a position in FOLD in Q3 2021 and held it in 11 quarters. The position peaked at $10.2M in Q4 2023. 259 funds tracked by Wall St. Rank hold FOLD as of Q2 2024.

  • MPM BioImpact reported no remaining Amicus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • MPM BioImpact sold 718,970 Amicus Therapeutics shares in Q2 2024, an estimated $8.47M.
  • MPM BioImpact first reported a position in Amicus Therapeutics in Q3 2021 and held it in 11 quarters.
  • MPM BioImpact's Amicus Therapeutics position peaked at $10.2M in Q4 2023.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2024.

Based on MPM BioImpact's 13F filing for Q2 2024, filed 14 Aug 2024.